Correlation between Serum Vitamin D and Soluble Urokinase Plasminogen Activator Receptor Levels in Patients with Extremely Drug-Resistant Tuberculosis at Vijayanagar Institute of Medical Sciences, Ballari, Karnataka
Authors/Creators
- 1. Assistant Professor, Department of Biochemistry, Vijaynagar Institute of Medical Sciences, Ballari, Karnataka, India
- 2. Associate Professor, Department of Biochemistry, Vijaynagar Institute of Medical Sciences, Ballari, Karnataka, India
Description
Background: Tuberculosis (TB) is a critical global health issue, further complicated by drug-resistant forms like extremely drug-resistant tuberculosis (XDR-TB).Vitamin D deficiency is known to be associated with many infectious and metabolic disorders. Vitamin D related receptors have been reported in multiple tissues, where they play key role in immune system modulation. High prevalence of Vitamin D deficiency in pulmonary TB patients indicates that Vitamin D is a risk factor for development of XDR-TB. Previous studies have shown that soluble urokinase plasminogen activator receptor (suPAR) may be used as TB treatment efficacy marker. suPAR is cellular receptor for serine protease urokinase plasminogen activator. Bacterial endotoxins and cytokines of innate immune system stimulate secretion of urokinase plasminogen activator (uPA) in monocytes and neurophils. Serum suPAR levels are elevated when TB is active and decreases when patient responds positively to therapy. Objective: To correlate between serum levels of vitamin D, known for its immune-regulating properties, and suPAR, an inflammation marker, in XDR-TB patients. Design: The study was conducted in the Department of Biochemistry, VIMS, Ballari, Karnataka. The study subjects were selected from district TB hospital of VIMS, Ballari. Controls: 36 age and sex matched healthy controls from the community selected. Case: 36 cases diagnosed with XDR-TB from District TB hospital, VIMS, Ballari. Methodology: Hb%, CBC, ESR, SGOT, SGPT, ALP, Blood Urea, Serum Creatinine, Serum Albumin, Serum Calcium, Serum Phosphorus were measured by standard procedures and Vitamin D levels by ELISA. Serum suPAR levels were measured by Quantitative sandwich enzyme immunoassay technique. Results: A significant inverse correlation was found between serum Vitamin D and suPAR levels, indicating that lower vitamin D levels are associated with higher immune activation and inflammation. Conclusion: The study suggests a link between vitamin D deficiency and increased inflammation in XDR-TB patients, highlighting the potential benefits of vitamin D monitoring and supplementation in managing this condition. Further research is needed to explore the therapeutic implications of vitamin D in TB.
Abstract (English)
Background: Tuberculosis (TB) is a critical global health issue, further complicated by drug-resistant forms like extremely drug-resistant tuberculosis (XDR-TB).Vitamin D deficiency is known to be associated with many infectious and metabolic disorders. Vitamin D related receptors have been reported in multiple tissues, where they play key role in immune system modulation. High prevalence of Vitamin D deficiency in pulmonary TB patients indicates that Vitamin D is a risk factor for development of XDR-TB. Previous studies have shown that soluble urokinase plasminogen activator receptor (suPAR) may be used as TB treatment efficacy marker. suPAR is cellular receptor for serine protease urokinase plasminogen activator. Bacterial endotoxins and cytokines of innate immune system stimulate secretion of urokinase plasminogen activator (uPA) in monocytes and neurophils. Serum suPAR levels are elevated when TB is active and decreases when patient responds positively to therapy. Objective: To correlate between serum levels of vitamin D, known for its immune-regulating properties, and suPAR, an inflammation marker, in XDR-TB patients. Design: The study was conducted in the Department of Biochemistry, VIMS, Ballari, Karnataka. The study subjects were selected from district TB hospital of VIMS, Ballari. Controls: 36 age and sex matched healthy controls from the community selected. Case: 36 cases diagnosed with XDR-TB from District TB hospital, VIMS, Ballari. Methodology: Hb%, CBC, ESR, SGOT, SGPT, ALP, Blood Urea, Serum Creatinine, Serum Albumin, Serum Calcium, Serum Phosphorus were measured by standard procedures and Vitamin D levels by ELISA. Serum suPAR levels were measured by Quantitative sandwich enzyme immunoassay technique. Results: A significant inverse correlation was found between serum Vitamin D and suPAR levels, indicating that lower vitamin D levels are associated with higher immune activation and inflammation. Conclusion: The study suggests a link between vitamin D deficiency and increased inflammation in XDR-TB patients, highlighting the potential benefits of vitamin D monitoring and supplementation in managing this condition. Further research is needed to explore the therapeutic implications of vitamin D in TB.
Files
IJPCR,Vol16,Issue5,Article220.pdf
Files
(402.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f342d54a3395c9ac175b7859b1b2f6bb
|
402.5 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue5,Article220.pdf
- Development Status
- Active
References
- 1. Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, Keshavjee S, Andersson J, Zumla A, Maeurer M. Totally drugresistant tuberculosis and adjunct therapies. Journal of internal medicine. 2015 Apr; 277(4):388-405. 2. Rathored J, Sharma SK, Singh B, Banavaliker JN, Sreenivas V, Srivastava AK, Mohan A, Sachan A, Harinarayan CV, Goswami R. Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25 (OH) D. The International Journal of Tuberculosis and Lung Disease. 2012 Nov 1;1 6(11):1522-8. 3. Asani FF. Expression of vitamin D receptor (VDR) and VDR target genes in an African and Caucasian population: the impact of vitamin Dand mycobacterial elicitation. University of Johannesburg (South Africa); 2014. 4. Zhang J, Chen C, Yang J. Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a metaanalysis of randomized controlled trials. Chinese medical journal. 2019 Dec 20;132 (24):2950-9. 5. Zavala K. Regulation of vitamin D metabolism during the immune response to mycobacterial infection (Doctoral dissertation, UCLA). 6. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy. Indian Journal of tuberculosis, vol64,no3/july2017. Indumati , V. Vijay, D. Krishnaswamy, V. Rajeshwari, A. Ramesh, D. Shantala, A. Shilpa 7. İLKİ AA. Tuberculosis and vitamin D. Marmara Medical Journal. 2014;27(2):85-. 8. Syal K, Chakraborty S, Bhattacharyya R, Banerjee D. Combined inhalation and oral supplementation of Vitamin A and Vitamin D: a possible prevention and therapy for tuberculosis. Medical hypotheses. 2015 Mar 1;84(3): 199-203. 9. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P. Management of patients with multidrugresistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. 10. Sharma D, Sharma S, Sharma J. Potential strategies for the management of drug-resistant tuberculosis. Journal of Global Antimicrobial Resistance. 2020 Sep 1;22:210-4. 11. Baeke F, Van Etten E, Overbergh L, Mathieu C. Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutrition research reviews. 2007 Jun;20(1):106-18. 12. Londt RS. Development of an Autologous Human Dendritic Cell Vaccine against Mycobacterium tuberculosis in Patients with Extensively Drug-Resistant Tuberculosis. 13. Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immunomodulator. Immunology. 2011 Oct;134(2):12 3-39. 14. Edem VF, Ige O, Arinola OG. Plasma vitamins and essential trace elements in newly diagnosed pulmonary tuberculosis patients and at different durations of anti-tuberculosis chemotherapy. Egyptian Journal of Chest Diseases and Tuberculosis. 2015 Jul 1;64(3):675-9. 15. Singh A, Gupta AK, Singh S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis: Role of nanoparticles against multidrug-resistant tuberculosis (MDR-TB). NanoBioMedicine. 2020:285-314.